New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
East Idaho News on MSN
Common questions about lung cancer
Lung cancer remains the leading cause of cancer-related death in the United States. The good news is that early detection ...
ABS-CBN on MSN
Understanding ILD: The rare lung disease
Spotting ILDs may be challenging. Symptoms such as a dry cough, shortness of breath, and unexplained weight loss may go ...
Adults with COPD receiving roflumilast had a smaller COPD exacerbation rate at 1 year vs. those receiving azithromycin but ...
There are steps physicians can take to prepare their patients with pulmonary issues for the changing of the seasons.
Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...
Reckitt, the maker of Mucinex®, the #1 physician-trusted cough and cold brand*, announced new outcomes from the Guaifenesin Assessment of Satisfaction for Patients (GASP) Study, the first long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback